The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure

American Journal of Medicine

Volumn 113, Issue 8, 2002, Pages 650-656

  Sin, Don D ^a   McAlister, Finlay A ^a  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL; NADOLOL; PINDOLOL; PROPRANOLOL DERIVATIVE; SOTALOL; TIMOLOL;

AGED; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART FAILURE; HEART RATE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; AGED; AGED, 80 AND OVER; ALBERTA; COHORT STUDIES; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036918486     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(02)01346-3     Document Type: Article

References (25)

1. Brophy J.M., Joseph L., Rouleau J.L. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med. 134:2001;550-560.
2. Jha P., Deboer D., Sykora K., Naylor C.D. Characteristics and mortality outcomes of thrombolysis trial participants and nonparticipants a population-based comparison. J Am Coll Cardiol. 27:1996;1335-1342.
3. Kramer M.S., Shapiro S.H. Scientific challenges in the application of randomized trials. JAMA. 252:1984;2739-2745.
4. Senni M., Tribouilloy C.M., Rodeheffer R.J., et al. Congestive heart failure in the community. A study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 98:1998;2282-2289.
5. Philbin E.F., Rocco R.A., Lindenmuth N.W., et al. Clinical outcomes in heart failure report from a community hospital-based registry. Am J Med. 107:1999;549-555.
6. Yusuf S. Digoxin in heart failure results of the recent digoxin investigation group trial in the context of other treatments for heart failure. Eur Heart J. 18:1997;1685-1688.
7. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302.
8. Packer M., Poole-Wilson P.A., Armstrong P.W., et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 100:1999;2312-2318.
9. Ikram H., Fitzpatrick D. Double-blind trial of chronic oral beta blockade in congestive cardiomyopathy. Lancet. 2:1981;490-492.
10. Rochon P.A., Tu J.V., Anderson G.M., et al. Rate of heart failure and 1-year survival for older people receiving low-dose beta-blocker therapy after myocardial infarction. Lancet. 356:2000;639-644.
11. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
12. Waagstein F., Bristow M.R., Swedberg K., et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial. Lancet. 342:1993;1441-1446.
13. Effect of metoprolol CR/XL in chronic heart failure Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 353:1999;2001-2007.
14. Garg R., Yusuf S. Overview of randomised trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 273:1995;1450-1456.
15. Barron H.V., Viskin S., Lundstrom R.J., et al. B-blocker dosages and mortality after myocardial infarction. Data from a large Health Maintenance Organization. Arch Intern Med. 158:1998;449-453.
16. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 45:1992;613-629.
17. Ghali W.A., Quan H., Brant R., et al. Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. JAMA. 286:2001;1494-1497.
18. Wen S.W., Hernandez R., Naylor C.D. Pitfalls in nonrandomized outcome studies the case of incidental appendectomy with open cholecystectomy. JAMA. 274:1995;1687-1691.
19. Bristow M.R., Gilbert E.M., Abraham W.T., et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 94:1996;2807-2816.
20. Massie B.M. 15 years of heart-failure trials what have we learned? Lancet. 352:(suppl I):1998;29-33.
21. Tu J.V., Austin P., Naylor C.D., et al. Acute myocardial infarction outcomes in Ontario methods appendix. Naylor C.D., Slaughter P.M. Cardiovascular Health and Services in Ontario an ICES Atlas. 1999;25-30 Institute for Clinical Evaluative Sciences, Toronto, Canada.
22. Goff D.C., Pandey D.K., Chan F.A., et al. Congestive heart failure in the United States. Is there more than meets the I(CD Code)? The Corpus Christi Heart Project. Arch Intern Med. 160:2000;197-202.
23. McAlister F.A., Teo K.K., Taher M., et al. Insights into the contemporary epidemiology and outpatient management of congestive heart failure. Am Heart J. 138:1999;87-94.
24. Clarke K.W., Gray D., Hampton J.R. Evidence of inadequate investigation and treatment of patients with heart failure. Br Heart J. 71:1994;583-587.
25. Chin M.H., Goldman L. Correlates of early hospital readmission or death in patients with congestive heart failure. Am J Cardiol. 79:1997;1640-1644.